BriaCell Therapeutics Corp. (NASDAQ:BCTX – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 1,320,000 shares, a decline of 5.7% from the December 15th total of 1,400,000 shares. Based on an average daily trading volume, of 236,800 shares, the days-to-cover ratio is presently 5.6 days. Approximately 12.7% of the company’s shares are sold short.
BriaCell Therapeutics Price Performance
NASDAQ:BCTX opened at $7.04 on Monday. The firm has a market cap of $109.25 million, a price-to-earnings ratio of -4.29 and a beta of 1.01. The firm’s fifty day moving average price is $5.59 and its 200 day moving average price is $6.16. BriaCell Therapeutics has a 1-year low of $4.06 and a 1-year high of $12.09.
BriaCell Therapeutics (NASDAQ:BCTX – Get Rating) last released its quarterly earnings data on Thursday, October 27th. The company reported ($1.01) EPS for the quarter. As a group, analysts expect that BriaCell Therapeutics will post -1.44 earnings per share for the current fiscal year.
Insider Activity at BriaCell Therapeutics
Institutional Trading of BriaCell Therapeutics
Large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of BriaCell Therapeutics during the 2nd quarter valued at about $60,000. Apollon Wealth Management LLC boosted its holdings in shares of BriaCell Therapeutics by 14.4% in the second quarter. Apollon Wealth Management LLC now owns 15,900 shares of the company’s stock valued at $92,000 after acquiring an additional 2,000 shares in the last quarter. Wasatch Advisors Inc. bought a new position in shares of BriaCell Therapeutics in the first quarter valued at approximately $2,481,000. Lynwood Capital Management Inc. lifted its position in shares of BriaCell Therapeutics by 94.8% in the 3rd quarter. Lynwood Capital Management Inc. now owns 1,198,000 shares of the company’s stock valued at $6,733,000 after acquiring an additional 583,000 shares in the last quarter. Finally, K.J. Harrison & Partners Inc raised its stake in BriaCell Therapeutics by 18.9% during the 2nd quarter. K.J. Harrison & Partners Inc now owns 1,607,027 shares of the company’s stock valued at $9,188,000 after purchasing an additional 255,245 shares during the period. Institutional investors and hedge funds own 16.34% of the company’s stock.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab.
- Get a free copy of the StockNews.com research report on BriaCell Therapeutics (BCTX)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.